Page 2 - Dermatology

Taro stake buyout to help operate dermatology biz profitably: Sun Pharma

Sun Pharma is looking to fully acquire its Israel-based unit Taro Pharmaceutical Industries in order to integrate the dermatology business with itself and keep it profitable amid increasing competition in the segment, according to Managing Director Dilip Shanghvi. The Mumbai-based drug major has proposed to fully acquire Taro through a reverse triangular merger. The company has issued a letter to the Taro board with a proposal containing a non-binding indication of interest to acquire all of the outstanding ordinary shares for a purchase price of USD 38 per ordinary share in cash. Sun Pharma currently owns around 78 per cent stake in Taro. "My own assessment is that the dermatology business, which is the primary focus for Taro, is a business under constant, increasing competition pressure," Shanghvi said in an analyst call. He further said: "And as a stand-alone company, it will be very difficult for Taro as an independent company to continue to operate that business profitably. S

USFDA puts partial clinical hold on Sun Pharma's dermatological drug

USFDA put a partial clinical hold on its application for an experimental dermatological drug due to the potential of thrombotic events

Eris Lifesciences buys dermatology brands from Dr Reddy's for Rs 275 crore

In January Eris had bought some derma brands from Glenmark Pharma as well

Eris Lifesciences Ltd buys 9 dermatology brands from Dr Reddy's for $33 mn

Eris and Dr. Reddy's did not immediately respond to Reuters' requests seeking the names of the dermatology brands

Expensive deal valuations to hit Torrent Pharma's near-term earnings

Sales trajectory in domestic formulations and resolution of regulatory issues are other triggers

Rise of cosmetic dermatology space gets big pharma looking for buyouts

According to reports, Torrent Pharmaceuticals is set to sign a deal to acquire Curatio Healthcare, a maker of skincare products, for Rs 2100 crore.

Eris acquires Oaknet Healthcare for Rs 650 cr for dermatology foray

With a revenue base of Rs 195 crore in FY22, Oaknet brings a portfolio of leading brands in dermatology and women's health to the Eris stable.

Tedious road to recovery: Covid is also altering people's signatures

Children, too, are experiencing aftereffects such as sleeplessness, fatigue, brain fog

Herpes, hair fall, nail issues: Doctors caution about post-Covid problems

From reactivation of herpes infection to loss of hair, several Covid patients in recovery phase are facing one dermatological complication or another due to lowered immunity, say doctors

Asset monetisation, sales uptick in US key triggers for Glenmark Pharma

The India business is expected to post double digit growth in FY22

Lockdown serves domestic pharma the bitter pill: April growth slips

Lack of fresh prescriptions drags growth in acute therapies

Rs 8,700 cr dermatology market is the new king in the pharma sector

Changing climatic conditions, higher pollution and increasing disposable incomes have contributed to the growth